CRBX Stock Overview
A biotechnology company develops health testing and microbiome modulators to address a range of chronic and metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Carbiotix AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.081 |
| 52 Week High | SEK 1.40 |
| 52 Week Low | SEK 0.036 |
| Beta | 1.08 |
| 11 Month Change | 43.46% |
| 3 Month Change | 31.82% |
| 1 Year Change | -93.40% |
| 33 Year Change | -99.40% |
| 5 Year Change | n/a |
| Change since IPO | -98.44% |
Recent News & Updates
Shareholder Returns
| CRBX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 1.5% | -2.1% | -3.6% |
| 1Y | -93.4% | 0.4% | 11.2% |
Return vs Industry: CRBX underperformed the Swedish Medical Equipment industry which returned 0.8% over the past year.
Return vs Market: CRBX underperformed the Swedish Market which returned 12.2% over the past year.
Price Volatility
| CRBX volatility | |
|---|---|
| CRBX Average Weekly Movement | 20.4% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.4% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CRBX's share price has been volatile over the past 3 months.
Volatility Over Time: CRBX's weekly volatility has decreased from 28% to 20% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Erik Deaner | carbiotix.com |
Carbiotix AB (publ), a biotechnology company develops health testing and microbiome modulators to address a range of chronic and metabolic diseases. Its portfolio includes prebiotic ingredients and diagnostic testing services. The company develops CarbiAXOS, a second-generation prebiotic soluble fiber based on virgin and upcycled natural substrates containing arabinoxylo-oligosaccharides that is customized to meet customer needs to the production of short chain fatty acids or any other effect; and LinkGut, a health test.
Carbiotix AB (publ) Fundamentals Summary
| CRBX fundamental statistics | |
|---|---|
| Market cap | SEK 16.32m |
| Earnings (TTM) | -SEK 15.16m |
| Revenue (TTM) | SEK 4.23m |
3.9x
P/S Ratio-1.1x
P/E RatioIs CRBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRBX income statement (TTM) | |
|---|---|
| Revenue | SEK 4.23m |
| Cost of Revenue | SEK 1.36m |
| Gross Profit | SEK 2.87m |
| Other Expenses | SEK 18.03m |
| Earnings | -SEK 15.16m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 67.88% |
| Net Profit Margin | -358.31% |
| Debt/Equity Ratio | 0% |
How did CRBX perform over the long term?
See historical performance and comparison